Presentations

  • “ Fillers and Neurotoxins: An Overview”, Innovations in Plastic Surgery: A Multidisciplinary Symposium, Cleveland Clinic Center for Continuing Education, March 2011
     
  • “Purified Polydimethylsiloxane, A Versatile Filler”,  American Academy of Dermatology Annual Meeting. San Francisco, California,  March 2006
     
  • “Latest News in Cosmetic Dermatology”, Porto Vita, Aventura, Florida,  April 2006
  • “What’s New in Fillers and Injectables. American Society” for Dermatologic Surgery, Palm Springs, California,  October 2006
     
  • “Cosmetic Dermatology Forum. Silicone and Sculptra.” American Academy of Dermatology, Washington DC, February 2007
     
  • Cosmetic Treatment of 225 Patients With Abobotulinumtoxina in a Private Practice” Florida Society of Dermatologic Surgeons, Orlando, Florida,  November 2009
     
  • Expert Panelist for Mescape Women’s Health CME- Accredited Course: “Evolving Options in Neurotoxins”, New York, New York,  April 2010
     
  • Abobotulinumtoxina/onabotulinumtoxinA: Advanced & Routine Uses in Daily Practice & Routine Uses in Daily Practice & Their Complications, Naples, Florida,  May 2010
     
  • “Fillers: Advanced Uses and Complications”. Florida Society of Dermatologic Surgeons, Orlando, Florida,  November 2011
     
  • Good Clinical Practice (GCP training), 10/23/2006 – Dermatology Research Institute SOP 5000. Based on NIH Clinical Research Training and educational standard issue by the NIH for conducting clinical research

Publications
Scientific Articles in Peer Review Journals:

  • Weber PJ, Gretzula Jc, Garland LD, Hevia O, Menn H.S. Syringoid Eccrine Carcinoma. J Dermatol Sug Oncol 1987; 13:64-67
     
  • Gretzula JC, Hevia O, Webber PJ. Bloom’s Syndrome. Primary Mucinous Carcinoma. J Dermatol Surg Oncol 1988; 14:170-172
     
  • Weber PJ, Hevia O, Gretzula JC, Robinovitz HC. Ruvalcaba-Myhre-Smith Syndrome. Pediatr Dermatol. 1988; 5: 28-32
  •  
  • Gretzula JC, Hevia O, Schachner LS, Et Al. Ruvalcaba-Myhre-Smith Syndrome, Pediatr Dermatol. 1988;5: 28-32
     
  • Weber PJ, Gretzula JC, Hevia O., Garland LB, Et Al. Dermatofibrosarcoma Protuberans. J Dermatol Surg. Oncol. 1988; 14:555-558
     
  • Porto R, Hevia O, Hensley GT, Meyer PR. Disseminated Klebsiella Rhinoscleromatis Infection. Arch Pathol Lab Med. 1988; 113: 1381-1383
     
  • Hevia O, Jiminez-Acosta F, Ceballos PI, Penneys NS. Pruritic Papuar Eruption of an AIDS Patient. A Clinico-Pathologic Study. J AM ACAD Dermatol.
     
  • Hevia O, Klingamn D, Penneys NS. Non-Scalp Hair Infection with Microsporum Canis in an AIDS Patient, J am ACAD Dermatol 1991 May: 24(5): 789-790
     
  • Hevia O, Nemeth AJ, Taylor JR. Tetinoin Accelerates Healing After Trichloracetic Acide Chemical Peel. Arch Dermatol 1991 Mat: 127(5): 678-682
     
  • Nemeth AJ, Eaglestein WH, Falanga V, Hevia O, Taylor JR. Methods to Speed Healing After Skin Biopsy and Trichloracetic Acid Chemical Peel. Prog Clin Biol Res. 1991; 365: 267-277
     
  • Breneman DL, Stewart D, Hevia O, Hino PD, Drake LA. A Double Blind Multicenter Clinical Trial Comparing Efficacy of Once-Daily Metronidazole 1% Cream to Vehicle in Patients with Rosacea. Cutis 1998 Jan: 61(1): 44-47
  •  
  • Weiss J, Menter A, Hevia O, Jones T, Et al. Treatment for 1,2, or 4 Weeks with 0.5% Fluorouracil Cream is Effective in the Treatment of Actinic Keratosis. J AM ACAD Dermatology. 2001
     
  • Hevia, O. A Retrospective Review of Calcium Hydroxylapatite for Correction of Volume Loss in the Infraorbital Region. Dermatol Surg. 2009 Oct; 35(10):1487-94
     
  • Hevia, O. Six-Year Experience Using 1,000 Centistoke Silicone Oil in 916 Patients for Soft-Tissue Augmentation in a Private Practice Setting. Dermatol Surg. 2009; 35:1646-52
     
  • Hevia, O. Retrospective Review of 500 Patients Treated With Abobotulinumtoxin A. J Drugs Derm. Sept; 2010

Submitted Abstracts

  • Retrospective Review of 500 Patients Treated with AbobotulinumtoxinA March 2010

Physician Training/Education

  • Medical Education Faculty for Bioform Medical Inc. 2008-2009
  • Belotero Dermal Filler Leaders Summit Moderator June 2010
  • Expert Panelist for Medscape CME Education “Options in Neurotoxin Treatment: Recent Literature, Evoloving Practice” Kane, Monheit, Hevia 6/25/2010
  • Medscape Education Ask the Expert Neurotoxin in Aesthetic Practice “Neurotoxin and Dermal Filler Combination Therapy: Which Product is Injected First?’ Oscar Hevia, MD 05/25/2010
  • Key Opinion Leader for Merz Aesthetics 2010-Current

Clinical Studies

Investigation for Following Studies:

  • A Double-Blind Study Comparing the Efficacy of a Topical Cream 1% Vehicle in the Treatment of Rosacea
     
  • A Comparative Study of the Cosmetic Characteristics of Psorcon Cream vs. Generic Fluocinonide 0.05%, Desoximetasone 0.05%, and Clobetasol Propionata Cream 0.05%
     
  • An Open-Label, Multicenter Trial to Evaluate the Safety and Effectiveness of Various Treatment Durations of Terbinafine in Patients with Onychomycosis in the Toenails
     
  • An Open-Label, Non-Controlled Study to Assess the Efficacy and Patient Acceptance of a Topical Ceam Monotherapy, Concomitant Therapy and Maintenance Therapy in the Treatment of Acne Vulgaris
     
  • A Double-Blind, Bilateral Comparison Study Comparing the Efficacy of 12% Glycolic Acid Cream vs. Vitamin C Solution in the Treatment of Photoaging
     
  • A Double-Blind, Bilateral Comparison Study Comparing the Efficacy of 2 Glycolic Acid Base Products in the Treatment of Photoaging
     
  • A Vehicle Controlled, Randomized, Double-Blind Study Comparing the Safety and Efficacy of DL-6025 0.05% Cream vs Vehicle in the Treatment of Actinic Keratosis
     
  • A Multi-centered Controlled, Double-Blind, Comparative Study of the Safety and Efficacy of DL-6035, 5% Benzoyl Peroxide, 1% Clindamycin, and Placebo Vehicle in the Treatment of Acne Vulgaris
  • A Prospective, Randomized, Comparative, Multicenter Study of Sensitization to Restylane and Perlane and Including an Acute Safety Profile Assessment. June 2005
     
  • A Prospective, Open Label, Randomized, Parallel Group, Dose Finding Study of Botulinum Toxin Type A for the Treatment of Moderate to Severe Platysmal Bands. August 2005
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Reloxin in the Treatment of Glabellar lines. October 2005
     
  • A Randomized, Multi-Center Study to Compare the Efficacy and Safety of Evolence (Dermicol P35) Versus Restylane for the Correction of the Soft Tissue Contour Deficiencies. October 2005
     
  • A Randomized, Evaluator-Blind, Multi-Center, Comparison of the Efficacy and Persistence of Correction of Nasolabial Folds with Restylane Using Two Different Re-Treatment Schedules November 2005
     
  • A Double Blind Dose Comparison of the Safety and Efficacy of Botox in the Treatment of Female Subjects with Moderate or Severe Glabellar Rhytids. April 2006
     
  • A Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Confirmatory Study of the Efficacy and Safety of Isolagen Therapy in the Treatment of Nasolabial Fold Creases. April 2006
     
  • Clinical Research Study to Histologically Evaluate the Persistence and Biocompatibility Changes of Four Different Types of Filler Materials on Human Subjects. April 2006
     
  • Prospective Clinical Research to Determine the Effect of Titan Light Based Device on Restylane Dermal Filler. October 2006
     
  • A Double Masked, Radomized, Multicenter, 2-Arm Parallel Study Comparing the Safety and Effectiveness of Aquamid and Restylane for the Aesthetic Treatment of Nasolabial Folds, December 2006
     
  • A Phase III, Randomized, Placebo-Controlled, Multicenter, Double-Blind Study of the Safety and Duration of Efficacy of Reloxin (Botulinum Type A Toxin) in Correction of Moderate to Severe Glabellar Lines (and Including a Sub-Sudty to Detect any Treatment Related QT Interval Changes. January 2007
     
  • A Multicenter, Open-label Feasibility Study of the Safety and Effectiveness of Juvederm Ultra Injectable Gel in Subjects who Desire Lip Enhancement August 2007
     
  • IT-A-008: A Phase III Double-Blind, Randomized, Placeo-Controlled Trial of the Safety and Eficacy of Isolagen Therapy in the Treatment of Moderate to Severe Facial Acne Scarring, November 2007
     
  • A Phase 3, Multi-Center Trial to Demonstrate the Safety and Efficacy of Repeat Treatment of Glabellar Rhytides (“Frown Lines”). PT-03B December 2007
     
  • Artes Medical Protocol #521-01: Protocol for the Post-Approval study of Artefill®  for Correction of Nasolabial Folds. January 2008
     
  • A Phase 3, Multicenter, Long Term, Repeat Treatment, Open Label, Single Arm Trial to Demonstrate the Safety of Repeat Treatment of Purtox for the Treatment of Glabellar Rhytids (“Frown Lines”) PT03C. February 2008